Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response

Clinical and Vaccine Immunology

Volumn 16, Issue 8, 2009, Pages 1121-1126

  Xu, Ying ^a,b   Liu, Wei ^a   Shen, Hongbo ^a   Yan, Jingran ^a   Qu, Di ^b   Wang, Honghai ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; CHIMERIC PROTEIN; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN 2C; PROTEIN AG85B; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BOVINE TUBERCULOSIS; CD4+ CD25+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL;

ACYLTRANSFERASES; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; SPLEEN; TH1 CELLS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 68149158107     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00112-09     Document Type: Article

References (29)

1. Andersen, P., and T. M. Doherty. 2005. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. 3:656-662.
2. Anonymous. 2008. Global tuberculosis control 2008: surveillance, planning, financing. WHO report. World Health Organization, Geneva, Switzerland.
3. Brandt, L., M. Elhay, I. Rosenkrands, E. B. Lindblad, and P. Andersen. 2000. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68:791-795.
4. Cai, H., D. H. Yu, X. Tian, and Y.X. Zhu. 2005. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol. 24:605-613. (Pubitemid 41483736)
5. + T cells in human tuberculosis. Proc. Natl. Acad. Sci. USA 97:12210-12215.
6. Darrah, P. A., D. T. Patel, P. M. De Luca1, R. W. B. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, M. Roederer, and R. A. Seder. 2007. Multifunctional TH1 cells define a correlate of vaccine mediated protection against Leishmania major. Nat. Med. 13:843-850.
7. Doherty, T. M., and G. Rook. 2006. Progress and hindrances in tuberculosis vaccine development. Lancet 367:947-949.
8. Eddine, A. N., and S. H. E. Kaufmann. 2005. Improved protection by recombinant BCG. Microbes Infect. 7:939-946.
9. Fine, P. E. M. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345.
10. Flynn, J. L. 2004. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinburgh) 84:93-101. (Pubitemid 38087953)
11. Flynn, J. L., M. M. Goldstein, K. J. Triebold, B. Koller, and B. R. Bloom. 1992. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89:12013-12017.
12. Grode, L., P. Seiler, S. Baumann, J. Hess, V. Brinkmann, A. N. Eddine, et al. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Investig. 115:2472-2479.
13. Hoft, D. F. 2008. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372:164-175.
14. + T-cell population. Vaccine 27:270-279.
15. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97:13853-13858.
16. MacMicking, J. D., G. A. Taylor, and J. D. McKinney. 2003. Immune control of tuberculosis by IFN-γ-inducible LRG-47. Science 302:654-659.
17. Martin, R. M., and A. M. Lew. 1998. Is IgG2a a good Th1 marker in mice? Immunol. Today 19:49.
18. North, R. J., and Y. J. Jung. 2004. Immunity to tuberculosis. Annu. Rev. Immunol. 22:599-623.
19. Olsen, A. W., L. A. H. van Pinxteren, L.M. Okkels, P. B. Rasmussen, and P. Andersen. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69:2773-2778.
20. Palendira, U., J. M. Spratt, W. J. Britton, and J. A. Triccas. 2005. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 23:1680-1685.
21. Ravn, P., A. Demissie, T. Eguale, H. Wondwosson, D. Lein, H. A. Amoudy, et al. 1999. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179:637-645.
22. Sousa, A. O., R. J. Mazzaccaro, R. G. Russell, F. K. Lee, O. C. Turner, S. Hong, et al. 2000. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc. Natl. Acad. Sci. USA 97:4204-4208.
23. Stephen, T. R., and S. H. E. Kaufmann. 2008. Rational design of vaccines against tuberculosis directed by basic immunology. Int. J. Med. Microbiol. 298:143-150.
24. Stover, C. K., G. P. Bansal, M. S. Hanson, J. E. Burlein, S. R. Palaszynski, J. F. Young, S. Koenig, D. B. Young, A. Sadziene, and A. G. Barbour. 1993. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178:197-209.
25. + T cells in vitro. Immunology 87:339-342.
26. van Pinxteren, L. A., J. P. Cassidy, B. H. Smedegaard, E. M. Agger, and P. Andersen. 2000. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30:3689-3698.
27. Xu, Y., B. Wang, J. Chen, Q. Wang, B. Zhu, H. Shen, Y. Qie, J. Wang, and H. Wang. 2006. Chimaeric protein improved immunogenicity compared with fusion protein of Ag85B and ESAT-6 antigens of Mycobacterium tuberculosis. Scand. J. Immunol. 64:476-481.
28. Xu, Y., B. Zhu, Q. Wang, J. Chen, Y. Qie, J. Wang, H. Wang, B. Wang, and H. Wang. 2007. Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-γ confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS Immunol. Med. Microbiol. 51:480-487.
29. Yu, D. H., M. Li, X. D. Hu, and H. Cai. 2007. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine 25:6744-6754.